Get the detailed quarterly/annual income statement for Abrdn Life Sciences Investors (HQL). Find out the revenue, expenses and profit or loss over the last fiscal year.

HQL offers a 12% yield, trades at a discount, and gives biotech-heavy healthcare exposure, though it's more volatile than ETFs like XLV. See why HQL CEF is a buy.

Tekla's biotech CEFs HQH and HQL keep dropping to lower and lower valuations with HQH now at a -11.6% discount and HQL at a -12.0% discount. Read more here.

PHILADELPHIA, PA / ACCESSWIRE / May 9, 2024 /abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH), (collectively, the "Funds") each, a closed-end management investment company ...

Okay, I've got two objects. There's the Hand object, and the Finger object. These are fake. The mappings are correct, I believe, everything works fine usually, I think I'm just misunderstanding ...